Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by Novartis

News   Mar 23, 2018 | Original story from The Wyss Institute

 
Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by Novartis

Made of the polymer that’s used in biodegradable sutures, this aspirin-sized device is designed to deliver immunotherapy agents that activate the immune system against tumors. Image courtesy of the Wyss Institute at Harvard University

 
 
 

RELATED ARTICLES

“Lymphoma Micro-reactor” Targets Chemo-Resistant Lymphoma

News

Researchers have developed a “lymphoma micro-reactor” device that exposes human lymphomas to fluid flow similar to that in the lymphatics and parts of the lymph node.

READ MORE

Researcher Patents Potential Vaccine Candidate for Syphilis

News

University of Victoria microbiologist Caroline Cameron and colleagues have received a patent for a potential vaccine candidate against syphilis.

READ MORE

Targeting Telomerase: A Therapeutic Strategy for Difficult-to-Treat Melanoma

News

Targeting telomerase was effective at killing NRAS-mutant melanoma cells, and the impact was further enhanced when the strategy was paired with an inhibitor of mitochondrial function, according to study results by The Wistar Institute published in Oncogene.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE